Applications of (+)-1,4-Di-O-Benzyl-D-Threitol in Industrial Manufacturing

As a core chemical intermediate, (+)-1,4-Di-O-Benzyl-D-Threitol supports several precise downstream applications in the pharmaceutical, fine chemical, and advanced material sectors. Our production adheres to high consistency and purity, enabling accurate performance in synthesis and process development. Below are key industry applications with focused compliance, formulation, integration, and finished goods details.

1. Chiral Ligand Synthesis for Asymmetric Catalysis

This material serves as a key intermediate for manufacturing chiral ligands, particularly in catalytic asymmetric reactions like Sharpless dihydroxylation. The molecule's stereochemistry and protected diol structure allow controlled modification to produce effective ligands for enantioselective transformations in pharmaceutical synthesis.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• ISO 9001:2015 Quality Management Systems in fine chemical production
• REACH Registration, Evaluation, Authorisation and Restriction of Chemicals (EU)
• USP General Chapter <232> and <233> for trace metal impurities, relevant to catalyst preparation

Typical usage ratio

• Ligand synthesis protocols typically use 1.0–1.2 molar equivalents relative to catalyst backbone precursors, depending on desired modification; process optimization may adjust excess to compensate for reaction conversion rates.

Downstream process integration

• Introduced after catalyst metal complex selection, either via direct coupling or multi-stage protection-deprotection procedures preceding final ligand workup.

Final product types

• Enantioselective chiral ligands for homogeneous and heterogeneous catalytic systems
• Fine chemicals for pharmaceutical intermediates manufacturing
• Stereoactive agents for specialty agrochemical synthetic pathways
• Research-grade ligand kits for academic and industrial R&D

2. API Intermediate Production in Nucleoside Synthesis

The compound functions as a protected diol intermediate enabling controlled glycosylation steps in the synthesis of nucleoside analogs. Its benzyl groups facilitate downstream deprotection, ensuring selective reactivity necessary in the chemical synthesis of antiviral and anticancer active pharmaceutical ingredients.

Industry compliance standards

• EU GMP Directive 2003/94/EC for API manufacture
• US FDA 21 CFR Part 210/211 for drug substance handling
• Ph. Eur. Monograph for Nucleoside and Nucleotide APIs
• ICH Q3C guidelines for residual solvents in peptide and nucleoside synthesis

Typical usage ratio

• Intermediate stages utilize 1.0–1.05 mol equivalents per nucleobase unit; scale-up batches may increase ratio to 1.1 depending on downstream purification yield requirements.

Downstream process integration

• Incorporated during protected sugar assembly prior to glycosylation, with process controls monitoring benzyl group stability; subsequent steps rely on hydrogenolysis for deprotection.

Final product types

• Antiviral nucleoside API intermediates (e.g., for HIV and Hepatitis drug candidates)
• Anticancer nucleoside derivatives
• RNA/DNA analog research reagents
• High-purity oligonucleotide building blocks

3. Construction of Chiral auxiliaries in Stereoselective Synthesis

It is utilized as a core scaffold for the manufacture of chiral auxiliaries, especially in asymmetric reductions and alkylation steps. The selective protection pattern enables customized functionalization and subsequent coupling, supporting complex molecule construction with defined stereocontrol.

Industry compliance standards

• ISO 13485:2016 for medical and laboratory chemical processing
• Japanese Pharmacopoeia (JP) regulations for chiral intermediates
• CLP Regulation (EC) No 1272/2008 for labeling and safe handling
• Standard Operating Procedures for Contract Development Manufacturing Organization (CDMO) batch scale-up

Typical usage ratio

• Generally 1.0 equivalent relative to substrate; auxiliary loading may reach up to 1.5 equivalents for challenging chiral induction steps.

Downstream process integration

• Introduced during auxiliary attachment or activation; typically removed by reductive or acidic cleavage after main stereochemical induction is achieved.

Final product types

• Chiral auxiliaries for enantioselective synthesis
• Stereospecific building blocks for agrochemical actives
• High-value specialty chemicals with configured centers
• Semisynthetic peptides and their protected intermediates

4. Fine Chemicals for High-Purity Protecting Group Chemistry

This raw material is adopted to introduce benzyl protecting groups into small-molecule synthesis workflows, where controlled, high-purity reaction mechanisms are necessary. Benzyl ethers formed via this molecule offer stability against common reagents and are removable under defined hydrogenolysis conditions, permitting stepwise synthetic design in advanced fine chemical production.

Industry compliance standards

• ISO 9001:2015 for fine and specialty chemical operations
• Responsible Care Global Charter for chemical manufacturing
• GLP (Good Laboratory Practice) for process validation and analytical quality
• REACH Annex VII for dossier information on chemical safety

Typical usage ratio

• Ratio varies from 0.95 to 1.2 equivalents depending on substrate reactivity and target yield; batch process protocols specify adjustment based on pre- and post-reaction analysis.

Downstream process integration

• Used in protection steps during multistep synthesis to safeguard diol groups, with subsequent deprotection scheduled near final product formation to minimize byproduct contamination.

Final product types

• High-purity fine chemical intermediates
• Specialty monomers for material science applications
• Benzyl-protected building blocks for fragrance, flavor, or bioactive compound development
• Chemical standards for analytical laboratories